Leerink Partners analyst Lili (Aurélie) Nsongo has reiterated their bullish stance on ARCT stock, giving a Buy rating on August 13.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lili (Aurélie) Nsongo’s rating is based on several promising developments within Arcturus Therapeutics’ pipeline and financial performance. The company is set to present initial Phase 2 data for ARCT-032 in cystic fibrosis, which shows potential as it includes patients who are ineligible for Class I modulators. This data, along with the anticipated completion of enrollment for the last cohort by the end of 2025, positions the company well for discussions with the FDA regarding a pivotal trial design in the first half of 2026.
Additionally, Arcturus is making progress with ARCT-810 for OTC deficiency, expecting regulatory alignment on Phase 3 design in the first half of 2026. The company’s vaccine franchise, in collaboration with CSL, is on track for a US BLA filing in the third quarter of 2025. Financially, Arcturus reported lower-than-expected R&D and SG&A expenses and maintains a strong cash position, which is expected to support its operations. These factors contribute to the positive outlook and Buy rating.
In another report released on August 13, Canaccord Genuity also maintained a Buy rating on the stock with a $66.00 price target.
ARCT’s price has also changed slightly for the past six months – from $15.860 to $14.890, which is a -6.12% drop .